Sonoma Bio inks $75M deal with Regeneron to advance cell therapies against autoimmunity


The news: Sonoma Biotherapeutics is partnering with Regeneron to co-develop cell therapies for Crohn’s disease and other autoimmune conditions. The agreement comes with a $75 million upfront payment and a potential $45 million milestone payment to Sonoma by Regeneron, a Tarrytown, N.Y.-based biotech giant. The deal builds on a massive $265 million Series B round raised in 2021 by Sonoma, a three-year old startup that operates in Seattle and South San Francisco.